High baseline body mass index predicts recovery of CD4+ T lymphocytes for HIV/AIDS patients receiving long-term antiviral therapy

PLoS One. 2022 Dec 30;17(12):e0279731. doi: 10.1371/journal.pone.0279731. eCollection 2022.

Abstract

The relationship between baseline BMI and CD4+ T cells during follow-up in HIV patients in China requires further evaluation. We conducted a retrospective cohort study based on adult AIDS patients who underwent or received antiretroviral therapy from 2003 to 2019 in Guangxi, China. BMI was divided into categories and compared, and after adjusting for BMI being related to the change in CD4 lymphocyte count, with normal weight as the reference group, the BMI before treatment was positively correlated with the changes in CD4+ T cells at different time periods. Among them, obese patients had significant CD4+ cell gain. In patients with pretreatment CD4+ T lymphocyte counts <200 cells/μL, a higher BMI was associated with an increased likelihood of achieving immunologic reconstitution [≥350 cells/μL: AHR: 1.02(1.01, 1.04), P = 0.004; ≥500 cells/μL: AHR: 1.03 (1.01, 1.05), P = 0.004]. Underweight in HIV patients was a risk factor for poor viral suppression [AHR: 1.24 (1.04, 1.48), P = 0.016]. Our study demonstrated that HIV/AIDS patients receiving ART with higher baseline BMI had better immune reconstitution and that baseline BMI could be an important predictor of immune reconstitution in patients receiving ART. Baseline BMI was not associated with virological failure, but a lower baseline BMI indicated poor viral suppression during follow-up.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome* / drug therapy
  • Adult
  • Antiretroviral Therapy, Highly Active
  • Antiviral Agents / therapeutic use
  • Body Mass Index
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes
  • China
  • HIV Infections* / drug therapy
  • Humans
  • Retrospective Studies
  • Viral Load

Substances

  • Antiviral Agents

Grants and funding

This study received support from the National Natural Science Foundation of China (Grant Nos. 81803295 and 81760602), the Natural Science Foundation of Guangxi (2018GXNSFAA138031), the “Thirteenth Five-Year” National Major Science and Technology Projects (2018ZX10715008–002 and 2018ZX10302104–001), the Innovation Project of Guangxi Graduate Education (YCSW2021143), and the Opening topic fund of Guangxi Key Laboratory of AIDS Prevention and Treatment (No.gklapt 201902). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.